News
The SELECT trial demonstrated a clear cardiovascular protection associated with semaglutide use, which could explain its ...
The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...
Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...
Table of Contents The Real Story Behind Your Changing Body Making Every Bite Count When You’re Eating Less Your Brain […] The ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
If all the Instagram posts and podcasts filling my feed are any indication, lots of 40- and 50-something women are spending ...
Explore more
Women and older adults using semaglutide, a popular anti-obesity medication, may face a heightened risk of muscle loss. A ...
Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...
India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...
GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...
People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...
Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results